Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTXBiotechnology
+$0.10 today
- Market cap
- $980.14M
- Beta
- 0.00
Volume 0.68M
Average 0.41M
SPTX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Depreciation & Amortization history
Currency unavailable · from the cash flow
No Depreciation & Amortization data reported for this period type.
Depreciation & Amortization vs competitors
How SPTX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $8.66M USD | +9.7% | — | 4.0% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1M USD | +7.4% | +296.1% | 5.0% |
| LTM Mar 2026 | $574K USD | -20.3% | +0.2% | — | |
| LTM Mar 2026 | $350K USD | +12.5% | +92.4% | — | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $328K USD | +19.3% | -0.6% | — |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $325.5K USD | — | +443.4% | — |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $59K USD | -90.6% | -29.5% | — |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding SPTX) | — | +8.6% | +46.3% | 4.5% | |
Competitors are the stored peer set for SPTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTX
Intrinsic Alpha fair value
Locked
Current Price
$18.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.